Literature DB >> 2434936

DNA synthesis in the canine prostate: effects of androgen and estrogen treatment.

E R Barrack, S J Berry.   

Abstract

Canine prostatic DNA synthesis was evaluated by measuring [3H]thymidine incorporation into DNA of tissue slices in vitro. Among untreated beagles, prostatic DNA synthesis rates in young dogs with normal prostates, young dogs with spontaneous benign prostatic hyperplasia (BPH), and old dogs with BPH were 676 +/- 186, 1,220 +/- 156, and 641 +/- 88 cpm/100 micrograms DNA/hr, respectively. Among 81 young beagles (intact or castrated) that had been treated for 4 months with various steroids, rates of DNA synthesis varied according to the type of hormonal treatment. Prostatic DNA synthesis (cpm/100 micrograms DNA/hr) was significantly different (P less than 0.001) for dogs treated with estradiol alone (1,658 +/- 221 cpm/100 micrograms DNA/hr; n = 10 dogs), androgen alone (testosterone, 5 alpha-dihydrotestosterone, or 5 alpha-androstane-3 alpha,17 beta-diol; 1,000 +/- 61 cpm/100 micrograms DNA/hr; n = 31 dogs). However, there was no correlation between prostate size and rate of DNA synthesis (cpm/100 micrograms DNA/hr). Although treatment with estrogen alone resulted in the highest rate of DNA synthesis, it produced squamous metaplasia and the smallest prostates; these results are indicative of a high rate of cell turnover. Comparing prostates that reached the same size following 4 months of treatment with androgen alone or androgen plus estrogen, the rate of prostatic cell turnover was lower in the androgen plus estrogen group. These results are interpreted to indicate an inhibitory effect of estradiol on the rate of cell death in the presence of androgens.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2434936     DOI: 10.1002/pros.2990100108

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  4 in total

1.  Increased COX-1 expression in benign prostate epithelial cells is triggered by mitochondrial dysfunction.

Authors:  Chandler N Hudson; Kai He; Laura E Pascal; Teresa Liu; Livianna K Myklebust; Rajiv Dhir; Pooja Srivastava; Naoki Yoshimura; Zhou Wang; William A Ricke; Donald B DeFranco
Journal:  Am J Clin Exp Urol       Date:  2022-08-15

2.  Qianliening capsule () inhibits human prostate cell growth via induction of mitochondrion-dependent cell apoptosis.

Authors:  Zhen-Feng Hong; Jiu-Mao Lin; Xiao-Yong Zhong; Ying Li; Jian-Heng Zhou; Wei Xu; Jun Peng
Journal:  Chin J Integr Med       Date:  2012-10-20       Impact factor: 1.978

3.  miRNA Regulation Network Analysis in Qianliening Capsule Treatment of Benign Prostatic Hyperplasia.

Authors:  Liya Liu; Yun Wan; Aling Shen; Jinyan Zhao; Jiumao Lin; Xiaoyong Zhong; Yuchen Zhang; Zhenfeng Hong
Journal:  Evid Based Complement Alternat Med       Date:  2015-07-30       Impact factor: 2.629

4.  Resveratrol Attenuates the Proliferation of Prostatic Stromal Cells in Benign Prostatic Hyperplasia by Regulating Cell Cycle Progression, Apoptosis, Signaling Pathways, BPH Markers, and NF- κB Activity.

Authors:  Jowon Jang; Junhui Song; Jiyun Lee; Sung-Kwon Moon; Bokyung Moon
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.